These data also suggest that dopamine agonist therapy should be further evaluated in acromegalic cats and particularly in those with smaller pituitary tumors, because resistance to dopamine agonist therapy has been associated with lower DRD2 expression in human GH-secreting adenomas [53]. This evidence concerns the gene DRD2 and pituitary tumor.